MannKind Corporation has announced that signed a marketing and distribution agreement with Australasian Medical & Scientific Ltd division AMSL Diabetes for commercialization of Afrezza inhaled insulin in Australia. AMSL Diabetes will take responsibility for getting Australian regulatory and reimbursement approval for Afrezza and for sales, marketing, and distribution if the inhaler is approved.
In the US, MannKind distributes Afrezza itself. In July 2018, the company announced that Tanner Pharma Group would distribute Afrezza in regions where it was not already approved. Mannkind had previously announced that Biomm would distribute Afrezza in Brazil and that Cipla would distribute the drug in India.
MannKind Corporation CEO Michael Castagna said, “We are excited to partner with AMSL Diabetes to accelerate patients’ access to Afrezza in Australia. This agreement with AMSL, our third international partnership for Afrezza, aligns us with a partner with a strong presence and knowledge of the diabetes market in Australia, giving us an opportunity to provide more healthcare providers and patients with a new option in their fight against diabetes.”
AMSL Managing Director Richard Plowright commented, “Adding Afrezza to our portfolio is a significant step towards addressing the needs of Australian patients with diabetes who are looking for a mealtime insulin with a unique time-action profile. Through our exclusive partnership with MannKind, we can bring the benefits of inhalable insulin to patients across Australia.”
Read the MannKind Corporation press release.
